Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Ani Pharmaceuticals (ANIP) Change in Intangibles (2016 - 2025)

Ani Pharmaceuticals (ANIP) has disclosed Change in Intangibles for 13 consecutive years, with $159000.0 as the latest value for Q4 2025.

Quarterly Change in Intangibles rose 84.88% to $159000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $20.5 million through Dec 2025, up 2757.18% year-over-year, with the annual reading at $20.5 million for FY2025, 2757.18% up from the prior year.
Change in Intangibles hit $159000.0 in Q4 2025 for Ani Pharmaceuticals, up from $60000.0 in the prior quarter.
In the past five years, Change in Intangibles ranged from a high of $21.0 million in Q2 2021 to a low of $4000.0 in Q4 2022.
Historically, Change in Intangibles has averaged $3.5 million across 5 years, with a median of $229000.0 in 2022.
Biggest five-year swings in Change in Intangibles: crashed 99.93% in 2021 and later soared 62400.0% in 2023.
Year by year, Change in Intangibles stood at $12000.0 in 2021, then plummeted by 66.67% to $4000.0 in 2022, then skyrocketed by 62400.0% to $2.5 million in 2023, then crashed by 96.56% to $86000.0 in 2024, then skyrocketed by 84.88% to $159000.0 in 2025.
Business Quant data shows Change in Intangibles for ANIP at $159000.0 in Q4 2025, $60000.0 in Q3 2025, and $2.9 million in Q2 2025.